{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:53:38Z","timestamp":1782489218100,"version":"3.54.5"},"reference-count":30,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council (NHMRC) Australia","award":["2013970"],"award-info":[{"award-number":["2013970"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,21]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Infections are a leading cause of non-relapse mortality following chimeric antigen receptor T-cell therapy (CAR-T) and bispecific antibody (BsAb) therapies. However, infection data from clinical trials are often incomplete, lack pathogen-level detail and rarely capture late infectious complications. This\n                      <jats:bold>C<\/jats:bold>\n                      AR-T treatment in\n                      <jats:bold>L<\/jats:bold>\n                      ymphoma:\n                      <jats:bold>A<\/jats:bold>\n                      nalysis of\n                      <jats:bold>R<\/jats:bold>\n                      isk of\n                      <jats:bold>I<\/jats:bold>\n                      nfection following\n                      <jats:bold>T<\/jats:bold>\n                      herap\n                      <jats:bold>y<\/jats:bold>\n                      (CLARITY) study aims to generate real-world, longitudinal infection data with extended follow-up to characterise infection timing, including late events and inform risk prediction in patients with lymphoma and myeloma receiving novel immunotherapies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>CLARITY is a multicentre observational cohort study across six Australian centres enrolling adults treated with CAR-T or BsAb therapies. A co-designed REDCap (Research Electronic Data Capture) instrument captures infections classified as microbiologically defined, clinically defined or fever of unknown origin, using internationally standardised definitions. Patients were enrolled between 2019 and 2023, with at least 2 years follow-up per patient, allowing time-updated data on immunosuppressive exposures, haematological recovery and prophylaxis. Multivariable regression and landmark analyses will estimate infection incidence and identify dynamic risk factors over time. Incidence rate ratios will assess prophylaxis effectiveness. Data integrity is supported by central adjudication and site-level audits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study has received a waiver of consent (HREC\/PMCC\/89002) and was co-designed by haematology and infectious diseases investigators. Findings will be disseminated through peer-reviewed publications, scientific meetings and national guideline committees to inform infection prevention and late effects surveillance in immunotherapy-treated populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111194","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:05:19Z","timestamp":1778166319000},"page":"e111194","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal real-world surveillance of infection outcomes in CAR-T and bispecific therapy recipients: the CLARITY study protocol"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-3592","authenticated-orcid":false,"given":"Gemma K","family":"Reynolds","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"},{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Department of Infectious Diseases and Immunology, Austin Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"},{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin W","family":"Teh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"},{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A","family":"Slavin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"},{"name":"National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026062608315060000_16.5.e111194.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03084-6"},{"key":"2026062608315060000_16.5.e111194.2","doi-asserted-by":"crossref","unstructured":"Tix T , Alhomoud M , Shouval R , et al . Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma. Mol Ther 2025. doi:10.1016\/j.ymthe.2025.03.048","DOI":"10.1016\/j.ymthe.2025.03.048"},{"key":"2026062608315060000_16.5.e111194.3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062608315060000_16.5.e111194.4","doi-asserted-by":"crossref","unstructured":"Teh BW , Mikulska M , Averbuch D , et al . Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Lancet Infect Dis 2024. doi:10.1016\/S1473-3099(23)00377-8","DOI":"10.1016\/S1473-3099(23)00377-8"},{"key":"2026062608315060000_16.5.e111194.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104134"},{"key":"2026062608315060000_16.5.e111194.6","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","article-title":"Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis","volume":"8","author":"Reynolds","year":"2024","journal-title":"Blood Adv"},{"key":"2026062608315060000_16.5.e111194.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43285","article-title":"National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval","volume":"6","author":"Cliff","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026062608315060000_16.5.e111194.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"2026062608315060000_16.5.e111194.9","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208943","article-title":"Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia","volume":"144","author":"Ge","year":"2024","journal-title":"Blood"},{"key":"2026062608315060000_16.5.e111194.10","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2024013859","article-title":"Improving infection reporting in hematology treatment trials","volume":"8","author":"Teh","year":"2024","journal-title":"Blood Adv"},{"key":"2026062608315060000_16.5.e111194.11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the american society of transplant and cellular therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026062608315060000_16.5.e111194.12","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25 Suppl 1","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2026062608315060000_16.5.e111194.13","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","article-title":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR","volume":"9","author":"Wudhikarn","year":"2025","journal-title":"Blood Adv"},{"key":"2026062608315060000_16.5.e111194.14","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv"},{"key":"2026062608315060000_16.5.e111194.15","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis","volume":"9","author":"van Besien","year":"2025","journal-title":"Blood Adv"},{"key":"2026062608315060000_16.5.e111194.16","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmi.2023.05.011","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026062608315060000_16.5.e111194.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000"},{"key":"2026062608315060000_16.5.e111194.18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.cmi.2024.11.008","article-title":"Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis","volume":"31","author":"Sassine","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026062608315060000_16.5.e111194.19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026062608315060000_16.5.e111194.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321"},{"key":"2026062608315060000_16.5.e111194.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"2026062608315060000_16.5.e111194.22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"2026062608315060000_16.5.e111194.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"},{"key":"2026062608315060000_16.5.e111194.24","doi-asserted-by":"crossref","DOI":"10.21037\/sci-2021-008","article-title":"Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting","volume":"8","author":"Thakkar","year":"2021","journal-title":"Stem Cell Investig"},{"key":"2026062608315060000_16.5.e111194.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026062608315060000_16.5.e111194.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"2026062608315060000_16.5.e111194.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"2026062608315060000_16.5.e111194.28","doi-asserted-by":"crossref","unstructured":"Rejeski K , Perez A , Iacoboni G , et al . The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer 2022;10. doi:10.1136\/jitc-2021-004475","DOI":"10.1136\/jitc-2021-004475"},{"key":"2026062608315060000_16.5.e111194.29","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026062608315060000_16.5.e111194.30","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N , Gribben J , Chabannon C , et al . The EBMT\/EHA CAR-T cell handbook. 2022.","DOI":"10.1007\/978-3-030-94353-0"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:42:24Z","timestamp":1782488544000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-111194"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111194","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}